PURPOSE: To compare corneal inflammation after syngeneic and allogeneic penetrating keratoplasty (PK) with miniature Keratoprosthesis (m-KPro) implantation in mice. METHODS: BALB/C (syngeneic) or C57BL/6 (allogeneic) corneas were transplanted onto BALB/C host beds as part of PK or m-KPro implantation. Corneal inflammation was assessed by determining the frequencies of CD45(+) leukocytes, CD4(+) T cells, CD11b(+) cells, and Gr-1(+) granulocytes/monocytes by flow cytometry at 2, 4, and 8 weeks post transplantation. In addition, expression levels of the proinflammatory cytokines TNF-α and IL-1β were analyzed using real-time qPCR at 8 weeks post transplantation. RESULTS: Cell frequencies in the syngeneic (syn) and allogeneic (allo) m-KPro groups were higher compared with the syngeneic and allogeneic PK groups, respectively, at all time points. However, after week 4, frequencies of all analyzed immune cells were higher in the alloPK group as compared with synKPro group. At 8 weeks, the expression of TNF-α was higher in synKPro, alloPK, and alloKPro groups compared with the naïve and synPK groups. The expression of IL-1β was significantly higher in both KPro groups as compared with PK groups. CONCLUSIONS: Although the m-KPro device augments the inflammatory response in the cornea after its implantation, allogenicity (of the carrier tissue) is also a significant contributor to corneal inflammation. These data suggest that using syngeneic or decellularized corneal tissue as a Boston-KPro carrier could reduce the postoperative inflammation response. Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc.
PURPOSE: To compare corneal inflammation after syngeneic and allogeneic penetrating keratoplasty (PK) with miniature Keratoprosthesis (m-KPro) implantation in mice. METHODS: BALB/C (syngeneic) or C57BL/6 (allogeneic) corneas were transplanted onto BALB/C host beds as part of PK or m-KPro implantation. Corneal inflammation was assessed by determining the frequencies of CD45(+) leukocytes, CD4(+) T cells, CD11b(+) cells, and Gr-1(+) granulocytes/monocytes by flow cytometry at 2, 4, and 8 weeks post transplantation. In addition, expression levels of the proinflammatory cytokines TNF-α and IL-1β were analyzed using real-time qPCR at 8 weeks post transplantation. RESULTS: Cell frequencies in the syngeneic (syn) and allogeneic (allo) m-KPro groups were higher compared with the syngeneic and allogeneic PK groups, respectively, at all time points. However, after week 4, frequencies of all analyzed immune cells were higher in the alloPK group as compared with synKPro group. At 8 weeks, the expression of TNF-α was higher in synKPro, alloPK, and alloKPro groups compared with the naïve and synPK groups. The expression of IL-1β was significantly higher in both KPro groups as compared with PK groups. CONCLUSIONS: Although the m-KPro device augments the inflammatory response in the cornea after its implantation, allogenicity (of the carrier tissue) is also a significant contributor to corneal inflammation. These data suggest that using syngeneic or decellularized corneal tissue as a Boston-KPro carrier could reduce the postoperative inflammation response. Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc.
Entities:
Keywords:
Boston Keratoprosthesis; allogeneic; cornea inflammation; penetrating keratoplasty; syngeneic
Authors: Joseph B Ciolino; Michael W Belin; Amit Todani; Khalid Al-Arfaj; Christopher J Rudnisky Journal: Ophthalmology Date: 2013-03-15 Impact factor: 12.079
Authors: Carlos A Medina; Alexander M Rowe; Hongmin Yun; Jared E Knickelbein; Kira L Lathrop; Robert L Hendricks Journal: Cornea Date: 2013-05 Impact factor: 2.651
Authors: Samer N Arafat; Marie-Claude Robert; Anita N Shukla; Claes H Dohlman; James Chodosh; Joseph B Ciolino Journal: Cornea Date: 2014-09 Impact factor: 2.651
Authors: Alja Črnej; Masahiro Omoto; Thomas H Dohlman; Miguel Gonzalez-Andrades; Eleftherios I Paschalis; Andrea Cruzat; T H Khanh Vu; Marianne Doorenbos; Dong Feng Chen; Claes H Dohlman; Reza Dana Journal: Invest Ophthalmol Vis Sci Date: 2016-04 Impact factor: 4.799